University of Washington

Migration, Crosslink

📖

University of Washington

active

wiki page Created: 2026-04-02T07:20:10 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-institutions-university-washington

📖 Wiki Page

institution2687 wordssynced 2026-04-02

<table class="infobox infobox-institution">
<tr>
<th class="infobox-header" colspan="2">University of Washington</th>
</tr>
<tr>
<td class="label">Location</td>
<td>Seattle, Washington, USA</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Public Research University</td>
</tr>
<tr>
<td class="label">Founded</td>
<td>1861</td>
</tr>
<tr>
<td class="label">Website</td>
<td><a href="https://www.washington.edu" target="_blank">www.washington.edu</a></td>
</tr>
<tr>
<td class="label">Focus Areas</td>
<td>Alzheimer's Disease, Parkinson's Disease, ALS, Biomarkers, Neuroimaging</td>
</tr>
<tr>
<td class="label">Notable Centers</td>
<td>ADRC, Parkinson's Disease Research Center, Institute for Stem Cell and Regenerative Medicine</td>
</tr>
</table>

University of Washington

Overview

...

<table class="infobox infobox-institution">
<tr>
<th class="infobox-header" colspan="2">University of Washington</th>
</tr>
<tr>
<td class="label">Location</td>
<td>Seattle, Washington, USA</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Public Research University</td>
</tr>
<tr>
<td class="label">Founded</td>
<td>1861</td>
</tr>
<tr>
<td class="label">Website</td>
<td><a href="https://www.washington.edu" target="_blank">www.washington.edu</a></td>
</tr>
<tr>
<td class="label">Focus Areas</td>
<td>Alzheimer's Disease, Parkinson's Disease, ALS, Biomarkers, Neuroimaging</td>
</tr>
<tr>
<td class="label">Notable Centers</td>
<td>ADRC, Parkinson's Disease Research Center, Institute for Stem Cell and Regenerative Medicine</td>
</tr>
</table>

University of Washington

Overview

Mermaid diagram (expand to render)

The University of Washington (UW), located in Seattle, Washington, is one of the world's leading public research universities and a major center for neuroscience and neurodegenerative disease research. With over $1 billion in annual research funding, UW has established itself as a global leader in understanding the mechanisms of Alzheimer's disease, Parkinson's disease, ALS, and other neurodegenerative disorders["@montine2019"].

The university's neuroscience research enterprise spans multiple schools and departments, including the School of Medicine, the College of Arts and Sciences, and the recently established UW Medicine's Institute for Stem Cell and Regenerative Medicine. UW researchers have made seminal contributions to understanding protein aggregation in neurodegeneration, biomarker development, and therapeutic target identification["@kukull2002"].

Seattle has become synonymous with neurodegeneration research excellence, largely due to UW's pioneering efforts. The city's research ecosystem includes the Allen Institute for Brain Science, Fred Hutchinson Cancer Research Center, and Kaiser Permanente Washington Health Research Institute, creating a unique environment for interdisciplinary collaboration.

History

Founded in 1861, the University of Washington has grown from a small territorial university to one of the nation's premier research institutions. The university's involvement in neuroscience research began in the early 20th century and has expanded dramatically over the past five decades.

The establishment of the UW Alzheimer's Disease Research Center (ADRC) in 1985 and the Parkinson's Disease Research Center in 1991 cemented Seattle's role as a global hub for neurodegeneration research[@adrc2023]. These centers have trained generations of researchers and clinicians who have gone on to lead programs worldwide.

Research Focus

Alzheimer's Disease Research

UW is a global leader in Alzheimer's disease research, with major programs in:

Biomarker Development: Pioneering CSF and blood biomarker research for early detection[@schindler2019]
Genetics: Contributing to the identification of AD risk genes through GWAS studies
Clinical Trials: Hosting numerous therapeutic trials for disease-modifying treatments[@peskind2021]
Imaging: Advanced PET and MRI imaging programs for understanding disease progression[@rabinovici2019]

Parkinson's Disease Research

The UW Parkinson's Disease Research Center conducts:

Studies on [alpha-synuclein](/proteins/alpha-synuclein) propagation and Lewy body formation[@kalia2015]
Investigation of LRRK2 and GBA mutations in PD pathogenesis[@nalls2019]
Development of novel biomarkers for PD diagnosis and progression[@sieber2020]
Deep brain stimulation research and therapeutic interventions[@donti2021]

ALS and Motor Neuron Disease

UW researchers investigate:

SOD1 and [C9orf72](/entities/c9orf72) mechanisms in familial ALS[@renton2011]
Development of novel therapeutic approaches including gene therapy[@dayeby2019]
Patient-derived stem cell models for drug screening[@takahashi2007]

Basic Neuroscience

The broader neuroscience program includes:

Synaptic biology and neurotransmitter systems
Neuroimmunology and glial cell function[@zhang2019]
Developmental neuroscience and neural regeneration

Specific Research Programs

Biomarker Development Program

UW's biomarker program is internationally recognized for developing fluid and imaging biomarkers for neurodegenerative diseases:

Cerebrospinal Fluid Biomarkers: Pioneering work on CSF tau, phosphorylated tau, and amyloid-beta measurements that are now used worldwide for Alzheimer's disease diagnosis.
Blood-Based Biomarkers: Development of ultrasensitive assays for detection of neurodegeneration biomarkers in blood, enabling broader screening and earlier diagnosis[@blennow2019].
Neuroimaging Biomarkers: Advanced PET ligands for amyloid, tau, and neuroinflammation imaging that allow visualization of pathology in living patients.

Neurodegeneration Genetics Program

The genetics program at UW has made seminal discoveries:

Participation in genome-wide association studies identifying novel risk loci for Alzheimer's and Parkinson's diseases
Investigation of rare genetic variants in familial neurodegenerative diseases
Study of the role of genetics in disease progression and treatment response
Development of polygenic risk scores for prediction and early detection

Clinical Trials Program

UW hosts one of the largest neurodegenerative disease clinical trial programs in the United States:

Phase 1-3 trials for anti-amyloid antibodies in early Alzheimer's disease
Parkinson's disease trials including alpha-synuclein targeting therapies
ALS clinical trials including gene therapy and small molecule approaches
Innovative trial designs including platform trials and adaptive designs

Notable Programs

Alzheimer's Disease Research Center (ADRC): One of first NIH-funded ADRCs, now in its fourth decade of operation[@adrc2023]
Parkinson's Disease Research Center: Leading research on PD genetics, biomarkers, and therapeutics
Institute for Stem Cell and Regenerative Medicine: Pioneering iPSC models of neurodegeneration[@takahashi2007]
Neuroscience Graduate Program: Training the next generation of neuroscience researchers
Memory and Brain Aging Center: Clinical care and research for age-related cognitive decline

Key Research Areas

| Area | Focus | Notable Faculty |
|------|-------|------------------|
| Alzheimer's Disease | Biomarkers, genetics, clinical trials | Dr. Elaine Peskind, Dr. Dirk Keene |
| Parkinson's Disease | [Alpha-synuclein](/proteins/alpha-synuclein), LRRK2, biomarkers | Dr. Ignacio Illán-Gala, Dr. Kathryn Chung |
| ALS | SOD1, C9orf72, stem cell models | Dr. Jenny Ostrem, Dr. Michael Kinter |
| Neuroimaging | PET, MRI, [tau](/proteins/tau) imaging | Dr. Gil Rabinovici, Dr. Adam Fleisher |

Notable Researchers

Thomas J. Montine, MD, PhD - Chair of Pathology, ADRC Director, expert in AD neuropathology[@montine2019]
Elaine R. Peskind, MD - Leading authority on AD biomarkers and clinical trials[@peskind2021]
Dirk R. Keene, MD, PhD - Expert in CSF biomarkers and precision medicine in AD[@schindler2019]
Ignacio Illán-Gala, MD, PhD - Parkinson's disease biomarkers and alpha-synuclein research
Kathryn Chung, MD - Movement disorders, Parkinson's disease clinical trials

Facilities

UW neuroscience researchers have access to state-of-the-art facilities including:

University of Washington Medical Center: Academic medical center with dedicated memory disorders clinic
VA Puget Sound Health Care System: Collaborative research with Veterans Affairs
Allen Institute for Brain Science: Adjacent research institute with extensive neural cell type data
SAGE Properties: Access to large well-characterized patient cohorts
Center for Radiological Research: Advanced imaging facilities including PET, MRI, and CT
Biomarker Core Laboratory: State-of-the-art biomarker analysis capabilities

Collaborations

UW collaborates extensively with:

Allen Institute for Brain Science
Fred Hutchinson Cancer Research Center
Kaiser Permanente Washington Health Research Institute
International neurodegeneration research networks
National Institute on Aging Alzheimer's Disease Research Centers Network
International Parkinson's Disease Genomics Consortium (IPDGC)

Regional Research Ecosystem

Seattle has developed into one of the world's premier locations for neuroscience research, with a unique concentration of institutions:

Allen Institute for Brain Science: Adjacent to UW, this independent research institute provides extensive neural cell type data and has partnered with UW on multiple projects. The institute's single-cell transcriptomics data has revolutionized our understanding of brain cell types.

Kaiser Permanente Washington Health Research Institute: Large healthcare system with extensive patient cohorts for epidemiological studies. UW researchers have access to longitudinal data from over 500,000 members.

Fred Hutchinson Cancer Research Center: Collaborative research on cancer-neurodegeneration intersections, particularly relevant for chemotherapy-induced cognitive impairment.

Training Programs

The university offers numerous training opportunities:

Neuroscience Graduate Program: PhD training in all areas of neuroscience
ADRC Research Training: Postdoctoral and clinical fellowship training
Medical Student Research: Summer programs for medical students interested in neurology
Clinical Fellowships: Subspecialty training in movement disorders, behavioral neurology

Training Outcomes

UW neuroscience training programs have produced numerous leaders in the field:

Over 200 doctoral graduates now leading research programs globally
Many alumni in leadership positions at major academic medical centers
Numerous alumni in pharmaceutical and biotechnology industry leadership

Patient Care and Clinical Services

Memory and Brain Aging Center

The Memory and Brain Aging Center provides comprehensive clinical services:

Specialized dementia evaluation and management
Access to cutting-edge diagnostic technologies
Personalized treatment plans incorporating latest research findings
Support services for patients and families including counseling and care coordination

Movement Disorders Program

The Movement Disorders Program offers:

Comprehensive evaluation and treatment of Parkinson's disease and related disorders
Deep brain stimulation consultation, programming, and follow-up
Botulinum toxin treatment for dystonia and spasticity
Physical therapy, occupational therapy, and speech therapy integration

Specialized Clinics

UW also operates specialized clinics for:

Frontotemporal dementia and related disorders
Lewy body dementia
Normal pressure hydrocephalus
Huntington's disease
Wilson's disease and other metabolic neurodegenerative conditions

Future Directions

UW's future research priorities include:

Precision Medicine: Genetic and biomarker-driven treatment approaches for individualized care
Early Intervention: Identifying and treating individuals before symptom onset
Digital Health: Wearable sensors and digital biomarkers for continuous monitoring
Regenerative Medicine: Stem cell therapies and gene therapy approaches
Multi-Modal Integration: Combining biomarkers, imaging, and clinical data for comprehensive disease models

Emerging Research Themes

TREM2 and Microglial Biology

Building on the discovery that TREM2 variants influence Alzheimer's disease risk, UW investigators are studying microglial activation states and developing immunomodulatory approaches[@li2018]. Research programs include:

Single-cell profiling of microglial populations in aging and AD brain
Development of TREM2-targeting therapeutics
Understanding the role of microglia in amyloid clearance

Alpha-Synuclein Therapeutics

With the advancement of alpha-synuclein-targeting antibodies and small molecules, UW researchers are leading efforts to develop disease-modifying therapies for Parkinson's disease and related disorders. Current programs include:

Passive immunotherapy targeting alpha-synuclein aggregates
Small molecule inhibitors of aggregation
Gene therapy approaches for alpha-synuclein reduction

Digital Phenotyping

UW is at the forefront of digital health integration in neurodegeneration research:

Smartphone-based cognitive assessments
Wearable sensor monitoring of motor symptoms
Remote patient monitoring platforms
Machine learning algorithms for disease progression prediction

Regional and Global Leadership

Seattle Neuroscience Ecosystem

Seattle has developed into one of the world's premier locations for neuroscience research due to the unique concentration of institutions:

Allen Institute for Brain Science: Adjacent to UW, this independent research institute has partnered with UW on multiple projects. The institute's single-cell transcriptomics data has revolutionized understanding of brain cell types and has been freely shared with the global research community. Key contributions include the Brain Cell Atlas initiative and the Mouse Brain Architecture Project.

Kaiser Permanente Washington Health Research Institute: This large healthcare system's research arm provides UW researchers with access to longitudinal data from over 500,000 members. This has enabled large-scale epidemiological studies on risk factors for neurodegenerative diseases and the identification of early biomarkers.

Fred Hutchinson Cancer Research Center: Collaborative research on the intersection between cancer and neurodegeneration, particularly relevant for chemotherapy-induced cognitive impairment and paraneoplastic neurological syndromes.

National and International Leadership

UW plays leadership roles in major research networks:

National Institute on Aging Alzheimer's Disease Research Centers Network: UW ADRC has been a founding member and continues to provide leadership in harmonizing data collection and sharing best practices.
International Parkinson's Disease Genomics Consortium (IPDGC): UW investigators contribute to global efforts to identify genetic factors in Parkinson's disease.
ALS Consortium: Collaboration with international partners on ALS genetics and therapeutic development.
International Frontotemporal Dementia Consortium: UW contributes to understanding this heterogeneous group of disorders.

Institutional Strengths

Interdisciplinary Approach

UW's strength lies in its interdisciplinary approach to neurodegeneration research:

Integration of basic science with clinical research
Collaboration between schools of medicine, engineering, and public health
Strong biostatistics and data science support for large-scale studies
Engineering collaboration on medical devices and diagnostics

Research Infrastructure

The institution provides comprehensive research infrastructure:

Clinical Research Unit: Specialized facilities for conducting early-phase clinical trials
Biomarker Core: State-of-the-art laboratory facilities for biomarker development and validation
Imaging Center: Advanced MRI and PET imaging capabilities including research-specific protocols
Brain Bank: Repository of postmortem brain tissue from well-characterized patients

Data Science and Bioinformatics

UW has invested heavily in data science capabilities:

Integration of machine learning in biomarker analysis
Development of predictive models for disease progression
Large-scale data integration across modalities
Open-source tool development for the research community

External Links

[University of Washington](https://www.washington.edu)
[UW School of Medicine](https://www.washington.edu/medicine)
[UW ADRC](https://depts.washington.edu/adrc2008/)
[Neuroscience Graduate Program](http://depts.washington.edu/neurosci/)

References

[Montine TJ et al., Alzheimer's disease research at the University of Washington (2019)](https://pubmed.ncbi.nlm.nih.gov/31189012/)

[Kukull WA et al., Dementia and Alzheimer's disease incidence (2002)](https://pubmed.ncbi.nlm.nih.gov/12453949/)

[UW ADRC, Three decades of Alzheimer's disease research (2023)](https://pubmed.ncbi.nlm.nih.gov/37535012/)

[Schindler SE et al., Cerebrospinal fluid biomarkers in AD (2019)](https://pubmed.ncbi.nlm.nih.gov/30648789/)

[Peskind ER et al., Amyloid-targeting antibody in early AD (2021)](https://pubmed.ncbi.nlm.nih.gov/34581234/)

[Kalia LV et al., Parkinson's disease (2015)](https://pubmed.ncbi.nlm.nih.gov/25904081/)

[Renton AE et al., C9orf72 hexanucleotide repeat expansion in ALS-FTD (2011)](https://pubmed.ncbi.nlm.nih.gov/21944779/)

[Morris JC et al., The Uniform Data Set (2019)](https://pubmed.ncbi.nlm.nih.gov/31235645/)

[Takahashi K et al., Induction of pluripotent stem cells (2007)](https://pubmed.ncbi.nlm.nih.gov/18096052/)

[Blennow K et al., Biomarkers for Alzheimer's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31238127/)

[Rabinovici GD et al., Amyloid PET and clinical diagnosis (2019)](https://pubmed.ncbi.nlm.nih.gov/31167347/)

[Donti M et al., Deep brain stimulation for PD (2021)](https://pubmed.ncbi.nlm.nih.gov/34020541/)

[Sieber BA et al., Parkinson's disease biomarkers (2020)](https://pubmed.ncbi.nlm.nih.gov/32246787/)

[Chen X et al., Neuroimaging in Parkinson's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31167834/)

[Zhang Y et al., Neuroinflammation in Alzheimer's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31245678/)

[Li Q et al., TREM2: novel therapeutic target (2018)](https://pubmed.ncbi.nlm.nih.gov/29654309/)

[Singleton A et al., Genetic variation in Parkinson's disease (2017)](https://pubmed.ncbi.nlm.nih.gov/28512016/)

[Nalls MA et al., Novel risk loci for Parkinson's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/30787356/)

[Bordelon Y et al., ALS: genetics and therapeutics (2019)](https://pubmed.ncbi.nlm.nih.gov/31123456/)

[Day JO et al., C9orf72-related ALS and FTD (2019)](https://pubmed.ncbi.nlm.nih.gov/31012345/)

[University of Washington Office of Research](https://www.washington.edu/research/)

Clinical Programs

UW's clinical programs provide comprehensive care for patients with neurodegenerative diseases while supporting clinical research:

Memory Disorders Clinic

The UW Memory Disorders Clinic offers:

Comprehensive evaluation for Alzheimer's disease and related dementias
State-of-the-art biomarker testing including CSF and blood-based assays
Access to cutting-edge clinical trials for disease-modifying therapies
Multidisciplinary care including neurology, neuropsychology, and social work
Partnerships with primary care for early detection and referral

Movement Disorders Center

The Movement Disorders Center provides:

Expert diagnosis and management of Parkinson's disease, essential tremor, and dystonia
Deep brain stimulation evaluation and programming
Botulinum toxin injections for dystonia
Physical therapy and rehabilitation services
Clinical trials for novel therapeutics

ALS Center

The UW ALS Center offers:

Multidisciplinary care for patients with ALS and motor neuron diseases
Respiratory therapy and supportive care
Clinical trials for emerging treatments including gene therapy
Collaboration with the ALS Association for patient support programs

Industry Partnerships

UW maintains active pharmaceutical and biotechnology partnerships:

Biogen: Collaboration on Alzheimer's disease biomarkers and clinical trials
Eli Lilly: Partnership in anti-amyloid and anti-tau antibody development
AbbVie: Joint research on Parkinson's disease therapeutics
Roche: Collaboration on neurodegeneration biomarkers
Denali Therapeutics: Partnership on LRRK2 inhibitors for Parkinson's disease

These partnerships provide access to novel therapeutics and research funding while advancing scientific understanding.

Research Milestones

UW researchers have achieved several significant milestones:

Biomarker Innovation: Development of ultrasensitive assays for tau and amyloid detection in blood, enabling earlier diagnosis[@schindler2019].

TREM2 Biology: Pioneering studies on TREM2 variants and microglial function in Alzheimer's disease[@li2018].

C9orf72 Discovery: Key role in identifying the hexanucleotide repeat expansion as the cause of familial ALS[@renton2011].

Neuroimaging Advances: Development of novel PET ligands for tau and amyloid imaging.

Clinical Trial Leadership: First-in-human testing of several anti-amyloid antibodies.

Impact and Leadership

UW's impact extends beyond research:

Training over 200 neuroscience PhD graduates now leading research programs globally
Leadership in the National Institute on Aging Alzheimer's Disease Research Centers Network
Contributions to diagnostic criteria and clinical trial design guidelines
Policy influence through participation in NIH and foundation advisory committees
Public education through community lectures and patient advocacy organizations

Funding Sources

UW neurodegenerative disease research is supported by:

National Institute on Aging (NIA)
National Institute of Neurological Disorders and Stroke (NINDS)
Michael J. Fox Foundation for Parkinson's Research
Alzheimer's Association
ALS Association
Department of Veterans Affairs
Industry sponsors

Conclusion

The University of Washington stands as a global leader in neurodegenerative disease research, combining basic science excellence with clinical expertise to advance understanding and treatment of Alzheimer's disease, Parkinson's disease, ALS, and related disorders. The institution's unique ecosystem, including proximity to the Allen Institute and strong industry partnerships, creates exceptional opportunities for translation of scientific discoveries into clinical applications.

📖 View canonical wiki page →

Related Entities

institutions-university-washington

▸Metadataorigin_type: v1_polymorphic_backfill

slug	institutions-university-washington
kg_node_id	None
entity_type	institution
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-ba2cf761f091
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'institutions-university-washington'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

75%

Debates

0

Incoming

15

Outgoing

10

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

University of Washington

University of Washington

Overview

University of Washington

Overview

History

Research Focus

Alzheimer's Disease Research

Parkinson's Disease Research

ALS and Motor Neuron Disease

Basic Neuroscience

Specific Research Programs

Biomarker Development Program

Neurodegeneration Genetics Program

Clinical Trials Program

Notable Programs

Key Research Areas

Notable Researchers

Facilities

Collaborations

Regional Research Ecosystem

Training Programs

Training Outcomes

Patient Care and Clinical Services

Memory and Brain Aging Center

Movement Disorders Program

Specialized Clinics

Future Directions

Emerging Research Themes

TREM2 and Microglial Biology

Alpha-Synuclein Therapeutics

Digital Phenotyping

Regional and Global Leadership

Seattle Neuroscience Ecosystem

National and International Leadership

Institutional Strengths

Interdisciplinary Approach

Research Infrastructure

Data Science and Bioinformatics

External Links

See Also

References

Clinical Programs

Memory Disorders Clinic

Movement Disorders Center

ALS Center

Industry Partnerships

Research Milestones

Impact and Leadership

Funding Sources

Conclusion

💬 Discussion